YOUR SEARCH FOR Text 112 RESULTS
1 of Total
What Can JAK Inhibition Do? More Than You Might Think | Incyte.com
… November 20, 2022 What Can JAK Inhibition Do? More Than You Might Think. Since our … Atta View Story … What Can JAK Inhibition Do? More Than You Might Think | Incyte.com …
2 of Total
Microsoft Word - Incyte Compliance Program for CA Final Nov 2011.doc
… Incyte Compliance Program for CA Final Nov 2011.doc …
3 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… for approval was based on the successful randomized REACH3 trial comparing ruxolitinib with … tafasitamab in combination with lenalidomide plus rituximab (R 2 ) versus R 2 in …
4 of Total
Privacy Policy | Incyte.com
… identified. Job Candidates Learn what we do with your personal information when you apply … Study Participants Learn what we do with your personal information when you are …
5 of Total
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Canc
… checkpoint inhibitors. These patients received doses of INCA33890 ranging from 100 mg to 1,500 … and 900 mg Q2W were selected as the recommended doses for expansion (RDE). Initial data (cut-off …
6 of Total
Corporate Governance | Incyte
… Audit & Finance Committee (opens in new window) Compensation Committee (opens in new window) Nominating & Corporate Governance Committee …
7 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Company’s clinical development portfolio. “Our double-digit growth in the first quarter … refractory B-cell malignancies: PoC with lenalidomide and plamotamab being initiated 2 …
8 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… is a Phase 3, global, multicenter, randomized, double-blind study evaluating …
9 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… the primary endpoint was met in its randomized, placebo-controlled, Phase 2 study … (INCB160058), a potent and selective JAK2 pseudokinase domain binder, cleared the …
10 of Total
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in
… met their primary endpoint at each tested dose (45 mg and 75 mg). A significantly higher … and STOP-HS2, povorcitinib treatment in both dosing groups resulted in continued improvements …